Spots Global Cancer Trial Database for A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Official Title: Phase 1b Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Study ID: NCT03797261
Study Description
Brief Summary: This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope /ID# 207393, Duarte, California, United States
USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States
University of Iowa Hospitals and Clinics /ID# 207459, Iowa City, Iowa, United States
Univ Kansas Med Ctr /ID# 207480, Kansas City, Kansas, United States
Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States
Washington University-School of Medicine /ID# 206995, Saint Louis, Missouri, United States
NYU Langone Medical Center /ID# 207390, New York, New York, United States
Unc /Id# 207388, Chapel Hill, North Carolina, United States
UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh, Pennsylvania, United States
Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia
Royal Adelaide Hospital /ID# 210602, Adelaide, South Australia, Australia
Alfred Health /ID# 210350, Melbourne, Victoria, Australia
Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt am Main, Hessen, Germany
Universitaetsklinikum Leipzig /ID# 209824, Leipzig, Sachsen, Germany
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 207987, Berlin, , Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 207803, Dresden, , Germany
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207788, Hamburg, , Germany
Contact Details
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
